Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2026 08:12 ET | Source: Sparian Biosciences, Inc

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NIH Grant

Sparian Biosciences initiates a phase 1 clinical trial of SBS-147, its next generation arylepoxamide receptor (AEAr) agonist for acute and chronic pain.
April 09, 2026 08:00 ET | Source: ZENTALIS PHARMACEUTICALS

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Planned interim analysis from DENALI Part 2a showed a clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles between the two dose groupsAzenosertib...
April 09, 2026 08:00 ET | Source: Cloudbreak Pharma, Inc.

Cloudbreak Pharma Announces Launch of Cloudbreakpharma.com to Raise Awareness of its Pipeline of Novel First-in-Class Therapeutics to Treat Serious Underserved Ophthalmic Diseases

Lead candidate, CBT-001 for the treatment of pterygium, a multi-billion-dollar addressable market, is in mid-Phase 3 with initial topline data anticipated in Q3 2026 Second asset, CBT-004 for the...
April 09, 2026 08:00 ET | Source: Cerevance, Inc.

Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting

Solengepras, a once-daily, oral, non-dopaminergic GPR6 inhibitor, demonstrated meaningful reductions in daily OFF time and improvements in sleep-related symptoms across two Phase 2 trialsMeeting...
April 09, 2026 08:00 ET | Source: Boehringer Ingelheim Limited

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer

Boehringer Ingelheim to evaluate innovative combination of DLL3‑targeting T‑cell engager plus PD‑L1/VEGF‑A bispecific antibody in small cell lung cancer.
April 09, 2026 08:00 ET | Source: Kyverna Therapeutics, Inc.

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026

EMERYVILLE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for...
April 09, 2026 07:01 ET | Source: Invivyd

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support...
April 09, 2026 07:00 ET | Source: Seres Therapeutics, Inc.

Seres Therapeutics to Present at CARB-X Investor Day

CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at...
April 09, 2026 06:30 ET | Source: Equinox Gold Corp.

Equinox Gold Delivers Strong First Quarter with 197,628 Ounces of Gold Production, $990 Million of Debt Reduction and Inaugural Dividend Payment

Equinox Gold announced Q1 2026 highlights, including 197,628 ounces of gold production, $990 million of debt reduction and inaugural dividend payment.
April 09, 2026 01:00 ET | Source: Idorsia Pharmaceuticals Ltd

Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development

Idorsia thanks Alberto Gimona – most recently Head of Global Clinical Development and Medical Affairs – and wishes him all the best for a well-deserved retirementAmer Joseph joins Idorsia as EVP,...